Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of herpes zoster subunit vaccine (ZOSTER-049; follow-up of ZOSTER-006/022)
jRCT1080223260Phase 4Completed
- Sponsor
- GSK
- Start
- Jul 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 4, open-label, single-arm trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by GSK. Primary endpoints: Prophylactic efficacy against herpes zoster, Safety of herpes zoster subunit vaccine over long-term follow-up and 1 more. Started Jul 2016; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on jRCT1080223260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223260.